WO2001053520A2 - Genchip für ein neugeborenen screening - Google Patents
Genchip für ein neugeborenen screening Download PDFInfo
- Publication number
- WO2001053520A2 WO2001053520A2 PCT/EP2001/000139 EP0100139W WO0153520A2 WO 2001053520 A2 WO2001053520 A2 WO 2001053520A2 EP 0100139 W EP0100139 W EP 0100139W WO 0153520 A2 WO0153520 A2 WO 0153520A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequences
- oligonucleotides
- carrier according
- nucleotide carrier
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- the invention relates to a nucleotide carrier for combined oligonucleotides with a selection of oligonucleotides for the detection of certain gene sequences and claims the priority of German patent application 100 02 446.7, to which reference is made in terms of content.
- Hybridization techniques i.e. the targeted attachment of two complementary nucleic acids to one another is an essential document in a large number of molecular biological processes. These techniques are used to detect individual genes or parts thereof in a preparation of genomic DNA or the transcription product of a gene (mRNA) [Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: A laboratory manual. 2nd ed., Vol. 2, 1989, Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 13.96-97; Constanzi C, Gillespie D: Fast blots: immobilization of DNA and RNA from cells. In: Guide to molecular cloning techniques.
- Hybridization is usually combined with a detection reaction and subsequent identification of a nucleic acid sequence.
- one strand of nucleic acid is marked, for example, by dyes, radioactivity or chemiluminescent or fluorescent molecules, while the second is bound to a solid phase.
- the solid phase is usually formed either by nitrocellulose or nylon membranes.
- genomic DNA or RNA the so-called target sequences
- target sequences are separated electrophoretically via an agarose gel, transferred to the nitro or nylon membrane and hybridized with a known DNA or RNA sequence as a probe.
- the hybridization is detected by a previous labeling of the probe and quantified if necessary.
- Hybridization of a probe with a target can now also be carried out using so-called gene chips [Lockhart DJ, Dong H, Byrne MC, Folettett MT, Gallo MV, Chee MS, Mittmann M, Wang C, Kobayashi M, Horton H and Brown EL. Expression Monitoring by Hybridization to High-Density Oligonucleotide Arrays. Nature Biotechnology. 14: 1675-1680, 1996; Wodicka L, Dong H, Mittmann M, Ho MH, and Lockhart DJ. Genome-wide expression monitoring in Saccharomyces cerevisiae. Nature Biotechnology. 15: 1359-1367.1997].
- Gene chips consist of a solid support made of, for example, a plastic or glass, to which up to several thousand oligonucleotides can be applied as probes.
- the surface of the chip which is only a few square centimeters in size, is covered with a "turf" of oligonucleotides with which the complementary nucleic acid sequences of a DNA or RNA sample can hybridize.
- the target sequences are marked beforehand in order to provide later detection of the hybridization.
- the use of gene chips allows the investigation of several thousand different sequences at the same time and thus represents an improvement over the conventional blot methods.
- the hybridization on the chip can be evaluated by a scanner, so that the method can be largely automated.
- Mutations in genes can be identified by sequencing the genetic information (Sanger et al., Proc. Natl. Acad. Sei. U.S.A. 74: 5463-5467, 1977).
- the sequencing of nucleic acids is usually very complex, so that in practice mutations are mostly indirect, i.e. by examining their biochemical and / or physiological effects using biochemical (e.g. enzyme-linked immunoassay), analytical (e.g. high-performance liquid chromatography, gas chromatography, or mass spectrometry) or bacteriological (so-called Guthrie growth inhibition test) procedures.
- the time period between the diagnosis of the gene defect and the beginning of the therapy or preventive measure must be kept as short as possible. This can be done by detecting the mutations directly, ie at the level of the nucleic acids. If possible, this should be done in early childhood.
- genetic aberrations can also be identified by means of the hybridization - already described. This has the advantage that the use of gene chips is possible and the effects of the automated evaluation techniques can be used.
- a DNA chip is known from US Pat. No. 5,837,832, with the aid of which known sequences can be sighted for possible mutations.
- a sequence which is complementary to the so-called reference sequence in question - the so-called wild-type sequence - is synthesized in sections each preferably having a length of 12 to 18 base pairs, as well as sequences which differ from these Widtype sequence sections only in a single base.
- the number of these so-called substitution sequences corresponds to the number of theoretically possible mutations through one base substitution each.
- the invention is therefore based on the object of providing a nucleotide carrier for combined oligonucleotides and a selection of sequences for a nucleotide carrier for combined oligonucleotides or a similar gene-combined examination means, in particular for a newborn screening, by means of which the genetic status of a defined combination is checked disease-relevant genes or gene segments (reference sequences) is possible.
- nucleotide carrier hereinafter “gene chip” with a selection of oligonucleotides with functionally characterized, known to cause certain phenotypes Mutations. These oligonucleotides can be identical or complementary to the reference sequences.
- the mutated oligonucleotides are specifically selected and combined from the spectrum of all theoretically possible mutations in the reference sequence segments.
- the mutations selected in this way, which cause a specific phenotype, are applied to the gene chip with at least one second phenotype-forming oligonucleotides.
- phenotype is broadly defined and refers to all forms, manifestations and consequences that are associated with a selected reference sequence or can be demonstrated by detecting these sequences.
- the phenotypes can be, for example, a body function, a physiological function, e.g. a metabolic disorder, or a genetic predisposition to an illness in the medical sense, e.g. a specific form of cancer.
- Another advantage of the gene chip according to the invention is that a fast, inexpensive and, above all, reliable examination method is provided, the sensitivity of which exceeds that of conventional physiological methods.
- a particularly preferred embodiment of the invention enables the checking of genetic states in the prenatal and neonatal area.
- a screening program for newborns can be a variety Detect genetic metabolic disorders using a small amount of blood.
- a selection of oligonucleotides for at least two or more, for example of the following diseases, can be put together on a chip:
- a chip with oligonucleotides for the diseases “phenylketonuria” and “galactosemia” is particularly preferred. This is preferably further combined with oligonucleotides for "biotinidase deficiency”.
- the diseases mentioned are caused by mutations in a total of 21 defined genes, which include around 150,000 nucleotides including the functionally relevant regulatory regions. Since each nucleotide can be present with one of the four bases adenine, guanine, cytosine and thymine, and insertions, deletions or inversions must also be considered, there are approximately 900,000 different mutation possibilities. Are more complex mutations such as So-called small indels (insertions / deletions), several million different mutations quickly result.
- a gene chip according to the prior art would accordingly have to have several million hybridization sites corresponding thereto. Such a number of sequences cannot be sensibly accommodated and evaluated on the known gene chips.
- oligonucleotides Through the selection of oligonucleotides according to the invention, the sequences required for the detection of the diseases on a gene chip, ie hybridization sites, can be reduced to approximately 5,000. This enables simultaneous mutation detection on a single gene chip. It is also possible to make a selection from the oligonucleotides required for the detection of the diseases listed above and to diagnose only one or a few of the diseases.
- These diseases diagnosed in this particular embodiment are a targeted selection of the most important genetically determined diseases in humans. They are also selected according to the criteria of treatability and the significant frequency in the population. Furthermore, they are essentially due to mutations that are already known. The functionally characterized mutations were combined, each causing 90 to 95% of the actual diseases observed.
- the gene chip according to the invention and the selection according to the invention are based on oligonucleotides for the detection of reference sequences, that is to say also sequences complementary thereto, which lie on 21 genes of the human genome. These are the following sequences, which are specified in their code of the gene bank of the National Center for Biotechnology Information (NCBI).
- NCBI National Center for Biotechnology Information
- Phenylalanine hydroxylase, PAH diagnosis of phenylketonuria [GenBank number: K03020, NM 000277, L47726, U49897].
- Cystathione beta synthase CBS [GenBank numbers: NM 000071, L14577, X98810 to X98823, X88562, X87815, X87816, X91910].
- ACADM medium-chain acyl-CoA dehydrogenase deficiency
- LDLR low-density lipoprotein receptor
- Apolipoprotein B (diagnosis of a defective apolipoprotein B)
- the gene chip according to the invention can therefore contain oligonucleotide sequences which are identical to the corresponding sections of the reference sequences or are complementary thereto. Furthermore, oligonucleotides can be applied which contain functionally characterized mutations or sequences complementary thereto.
- the mutations can be base substitutions, insertions and deletions. More complex mutations such as inversions and indels (as insertions / deletions) are also possible.
- the length of the oligonucleotides applied to the gene chip can be 16 to 25 nucleotides. Preferably 15 to 18 mers are used.
- the sequences which are complementary thereto can be synthesized from the sample to be examined. This synthesis takes place during the labeling reaction necessary for the later detection of the hybridization that has taken place.
- DNA and RNA sequences can be applied to the gene chip according to the invention. Accordingly, nucleotides with uracil can be used. Base analogs can also be used.
- Oligonucleotides that are complementary to sequences of the reference sequences listed in Table 1 are applied to a suitable support using standard techniques, such as are described, for example, in German Patent 196 12 356 or US Pat. No. 5 837 832. This is preferably made of glass coated with gold.
- the oligonucleotides are 15 nucleotides in length. In individual cases, sequences of 16 to 25 nucleotides are also possible.
- the carrier is divided into a plurality of fields, each of which contains only one sequence comprising one mutation.
- the sequences are positioned within the field in such a way that the mutation is as central as possible relative to the reference sequence section.
- the field 1.1 the sequence CAGTGGACATGCTGG, which is complementary to the reference sequence section CCAGCATGTCCACTG (table, line 1, column 2) and the field 1.2 the corresponding mutated oligonucleotide CAGTGGAIATGCTGG, which is complementary to the mutated reference sequence section CCAGCATATCCACTG (column 3, table 3; Mutation underlined).
- Table 1 List of nucleic acid sequences, the complementary sequences of which are applied to the chip. In order to maintain clarity, only the central area of the 15- to 25-mers is shown as a section. The sequence sections not listed are complementary to the reference sequence. The position relative to the reference sequence results from the specification of the codon number.
- oligonucleotide complementary to the mutated reference sequence section is applied to the support at a precisely defined location.
- the nucleotides deviating from the reference sequence result from column 3 of the table.
- sequence information listed in the table relates to the reference sequence with the GenBank number U49897. There are both mis sense or nonsense mutations (Table 1A) and splice variants (Table 1B), deletions (Tables 1C and 1E); Insertions (table 1 D), indels and complex rearrangements selected.
- Column 1 shows the number of the codon affected by the mutation on the reference sequence. The last column shows the amino acid exchange encoded by the mutation.
- Exon 3 plus flanking sequences 22 bp, starting with nucleotide 593, codon 198 22 bp starting with nucleotide 586, codon 196 265 bp relate to exons 5-6 exons 1-5 plus flanking sequences. Exons 9-13 plus flanking sequences. 22 bp starting with nucleotide 589, codon 197 exons 9-11 plus flanking sequences
- Biotinidase, BTD (diagnosis of a biotinidase deficiency).
- ACADM medium-chain acyl-CoA dehydrogenase deficiency
- LDLR low-density lipoprotein receptor
- Apolipoprotein B (diagnosis of a defective apolipoprotein B).
- a selection of oligonucleotides complementary to functionally characterized mutations is applied to the gene chip according to the invention for a newborn screening. These mutations are in Tables 6.1.1. to 6.12.5 specified in their position on the reference sequence and the amino acids concerned.
- the oligonucleotides of the reference sequence listed in Table 3 are applied directly to a suitable support using the known standard techniques. Analogously to Example 1, 15-mer is generally used, but in individual cases 16- to 25-mer oligonucleotides can also be used.
- sequences are in turn chosen so that the sequence deviation present in the mutated reference sequence is approximately central relative to the reference sequence.
- Table 3 contains a list of the nucleic acid sequences that are applied to the chip for diagnosing the biotinidase deficiency. For the sake of clarity, only the central area of the 15 to 25-mer oligonucleotides is shown. The position is specified relative to the reference sequence by specifying the codon number. The normal reference sequence shown in the third column is applied to each mutated reference sequence at a precisely defined location on the support. The sequence sections not shown correspond to the reference sequence.
- Table 4 Diseases recognized with a nucleotide carrier according to the invention.
- This table shows the congenital hereditary diseases and the relevant reference sequences which can be diagnosed with the nucleotide carrier described in the exemplary embodiment. It also contains information on what percentage of clinical diseases is caused by mutations in the corresponding genes that have already been described.
- Tables 6.1.1 to 6.12.5 specify the oligonucleotides relevant to certain diseases on the nucleotide carrier (NT), namely in this relative position, the genes concerned, the number of the codon of the reference sequence, the nucleotides of the reference sequence concerned, the mutated sequences, and the phantopy consequences of the mutations. For reasons of clarity, only the sequence area directly affected is shown. The sections of the oligonucleotides not listed are either identical to the corresponding sequence of the reference sequence or complementary. Deleted nucleotides are shown in lower case.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002398058A CA2398058A1 (en) | 2000-01-21 | 2001-01-09 | Gene chip for neonate screening |
AU2001235400A AU2001235400A1 (en) | 2000-01-21 | 2001-01-09 | Gene chip for neonate screening |
EP01907415A EP1301622A2 (de) | 2000-01-21 | 2001-01-09 | Genchip für ein neugeborenen screening |
JP2001553380A JP2004500076A (ja) | 2000-01-21 | 2001-01-09 | 新生児スクリーニングのためのジーンチップ |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10002446.7 | 2000-01-21 | ||
DE10002446A DE10002446A1 (de) | 2000-01-21 | 2000-01-21 | Genchip für ein Neugeborenen Screening |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001053520A2 true WO2001053520A2 (de) | 2001-07-26 |
WO2001053520A3 WO2001053520A3 (de) | 2003-01-23 |
Family
ID=7628226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2001/000139 WO2001053520A2 (de) | 2000-01-21 | 2001-01-09 | Genchip für ein neugeborenen screening |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1301622A2 (de) |
JP (1) | JP2004500076A (de) |
AU (1) | AU2001235400A1 (de) |
CA (1) | CA2398058A1 (de) |
DE (1) | DE10002446A1 (de) |
WO (1) | WO2001053520A2 (de) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072882A2 (de) * | 2001-03-13 | 2002-09-19 | Ogham Gmbh | Herzchip |
EP1398388A2 (de) * | 2002-08-09 | 2004-03-17 | OGHAM GmbH | Methode zur Bestimmung eines erblichen Thromboserisikos mit DNA-arrays |
US20090317797A1 (en) * | 2005-01-18 | 2009-12-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Non-Invasive, Prenatal, In-Vitro Method for Detecting the Normal Healthy Condition, the Condition of a Healthy Carrier or the Condition of a Carrier Inflicted with Cystic Fibrosis |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5401516A (en) * | 1992-12-21 | 1995-03-28 | Emisphere Technologies, Inc. | Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0256630A1 (de) * | 1986-07-31 | 1988-02-24 | Howard Hughes Medical Institute | Spezifische Sonde zur Identifikation von Mutationen in den humanen Phenylalaningenen |
US5750335A (en) * | 1992-04-24 | 1998-05-12 | Massachusetts Institute Of Technology | Screening for genetic variation |
EP0962464A2 (de) * | 1996-01-23 | 1999-12-08 | Rapigene, Inc. | Methoden und Zusammensetzungen zum Nachweis der Bindung eines Liganden-Paars mittels nicht-fluoriszierender Markierungen |
-
2000
- 2000-01-21 DE DE10002446A patent/DE10002446A1/de not_active Withdrawn
-
2001
- 2001-01-09 EP EP01907415A patent/EP1301622A2/de not_active Withdrawn
- 2001-01-09 JP JP2001553380A patent/JP2004500076A/ja active Pending
- 2001-01-09 AU AU2001235400A patent/AU2001235400A1/en not_active Abandoned
- 2001-01-09 CA CA002398058A patent/CA2398058A1/en not_active Abandoned
- 2001-01-09 WO PCT/EP2001/000139 patent/WO2001053520A2/de not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0256630A1 (de) * | 1986-07-31 | 1988-02-24 | Howard Hughes Medical Institute | Spezifische Sonde zur Identifikation von Mutationen in den humanen Phenylalaningenen |
US5750335A (en) * | 1992-04-24 | 1998-05-12 | Massachusetts Institute Of Technology | Screening for genetic variation |
EP0962464A2 (de) * | 1996-01-23 | 1999-12-08 | Rapigene, Inc. | Methoden und Zusammensetzungen zum Nachweis der Bindung eines Liganden-Paars mittels nicht-fluoriszierender Markierungen |
Non-Patent Citations (3)
Title |
---|
CRONIN M T ET AL: "CYSTIC FIBROSIS MUTATION DETECTION BY HYBRIDIZATION TO LIGHT-GENERATED DNA PROBE ARRAYS" HUMAN MUTATION, WILEY-LISS, NEW YORK, NY, US, Bd. 7, 1996, Seiten 244-255, XP000991050 ISSN: 1059-7794 * |
EIKEN H G ET AL: "APPLICATION OF NATURAL AND AMPLIFICATION CREATED RESTRICTION SITES FOR THE DIAGNOSIS OF PKU MUTATIONS" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, Bd. 19, Nr. 7, 11. April 1991 (1991-04-11), Seiten 1427-1430, XP000371877 ISSN: 0305-1048 * |
EIKEN HANS GEIR ET AL: "A de novo phenylketonuria mutation: ATG (Met) to ATA (Ile) in the start codon of the phenylalanine hydroxylase gene." HUMAN MUTATION, Bd. 1, Nr. 5, 1992, Seiten 388-391, XP001073536 ISSN: 1059-7794 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002072882A2 (de) * | 2001-03-13 | 2002-09-19 | Ogham Gmbh | Herzchip |
WO2002072882A3 (de) * | 2001-03-13 | 2003-10-02 | Ogham Gmbh | Herzchip |
EP1398388A2 (de) * | 2002-08-09 | 2004-03-17 | OGHAM GmbH | Methode zur Bestimmung eines erblichen Thromboserisikos mit DNA-arrays |
EP1398388A3 (de) * | 2002-08-09 | 2004-06-16 | OGHAM GmbH | Methode zur Bestimmung eines erblichen Thromboserisikos mit DNA-arrays |
US20090317797A1 (en) * | 2005-01-18 | 2009-12-24 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Non-Invasive, Prenatal, In-Vitro Method for Detecting the Normal Healthy Condition, the Condition of a Healthy Carrier or the Condition of a Carrier Inflicted with Cystic Fibrosis |
Also Published As
Publication number | Publication date |
---|---|
CA2398058A1 (en) | 2001-07-26 |
WO2001053520A3 (de) | 2003-01-23 |
AU2001235400A1 (en) | 2001-07-31 |
DE10002446A1 (de) | 2001-08-16 |
JP2004500076A (ja) | 2004-01-08 |
EP1301622A2 (de) | 2003-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69535428T2 (de) | Verfahren zum Auffinden von differentiel exprimierte Gene | |
DE69828392T2 (de) | Verfahren zur Herstellung eines diagnostischen Standard-Gentranskriptionsmusters | |
EP0438512B2 (de) | Verfahren zur analyse von längenpolymorphismen in dna-bereichen | |
DE69834127T2 (de) | Diagnostischer test auf spinocerebellar ataxia typ 6 | |
WO2001077384A2 (de) | DETEKTION VON SNPs UND CYTOSIN-METHYLIERUNGEN | |
EP0925373A1 (de) | Verfahren zum nachweis von nukleinsäuren unter ermittlung der masse | |
DE60036750T2 (de) | Verfahren zur Abschätzung der Sensitivität für Osteoporose-Medikamente | |
WO2001053520A2 (de) | Genchip für ein neugeborenen screening | |
DE112009001722B4 (de) | Verfahren zur Diagnose von Legasthenie | |
EP1960537A1 (de) | Verfahren zur bestimmung des genotyps aus einer biologischen probe enthaltend nukleinsäuren unterschiedlicher individuen | |
WO2005071107A1 (de) | A141s- und g399s-mutation im omi/htra2-protein bei morbus parkinson | |
Courret et al. | The evolutionary history of Drosophila simulans Y chromosomes reveals molecular signatures of resistance to sex ratio meiotic drive | |
EP1305449A2 (de) | Diagnose von mit cd24 assoziierten krankheiten | |
EP1537246B1 (de) | Verfahren zur Amplifikation genetischer Information mittels an mehrere Stellen im Genom bindende Primer | |
EP3103882B1 (de) | Verfahren zur genbasierten diagnose eines legasthenierisikos | |
EP1368492A2 (de) | Herzchip | |
DE10160563B4 (de) | Verfahren zur Untersuchung der erblichen Infertilität des Mannes | |
EP1194589B1 (de) | Dna-polymorphismen in sterol-regulator element-bindenden proteinen | |
DE69834831T2 (de) | Gen, das im zusammenhang steht mit gemütskrankheiten | |
EP2129798A2 (de) | Organismusspezifisches hybridisierbares nucleinsäuremolekül | |
EP1159449A2 (de) | Testsystem zum nachweis einer spleissreaktion, sowie dessen verwendung | |
DE60109002T2 (de) | Methode zum Nachweis von transkribierten genomischen DNA-Sequenzen | |
WO2004042081A1 (de) | Spezifische haplotypen des mdr1-gens und deren anwendung in der diagnose und therapie | |
Ewald | Genetics of bipolar affective disorder | |
Gilliam et al. | Huntington's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2398058 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 553380 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001907415 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001235400 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001907415 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001907415 Country of ref document: EP |